Statin-Cannabinoid Compositions for Reduced Muscle Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current statin treatments for hypercholesterolemia are effective but suffer from significant adverse effects such as muscle problems, kidney issues, and increased risk of diabetes and cognitive impairment, limiting their use due to safety concerns.
Innovation Solution
The development of pharmaceutical compositions that combine a statin with a cannabinoid, specifically cannabidiol (CBD), to enhance the antihypercholesterolemic effect of statins while reducing adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If statins are used to treat hypercholesterolemia, then LDL cholesterol levels are reduced, but muscle problems and adverse effects occur
Solution Approach 1:
The patent combines statin therapy with cannabinoid compounds (particularly CBD) to create a synergistic treatment approach. The cannabinoid component enhances the lipid-lowering efficacy of statins while simultaneously reducing statin-induced muscle toxicity, thereby resolving the contradiction between therapeutic effectiveness and adverse effects.
Solution Approach 2:
Cannabinoid compounds act as intermediary agents that modulate the interaction between statins and muscle tissue. The cannabinoids reduce the direct toxic effect of statins on muscle cells while preserving the cholesterol-lowering mechanism, thus mediating the harmful effects without compromising therapeutic benefits.
2Reliability
If higher doses of statins are administered, then cholesterol lowering effect is enhanced, but adverse effects increase in frequency and severity
Solution Approach 1:
The combination of statins with cannabinoid compounds allows for achieving enhanced cholesterol lowering effects without proportionally increasing adverse effects. The cannabinoid component provides a protective effect that decouples the dose-response relationship between statin dosage and muscle toxicity, enabling safer administration of effective doses.
3Duration of action of stationary object
If statin therapy is continued long-term, then cardiovascular risk is reduced, but cumulative adverse effects accumulate
Solution Approach 1:
Cannabinoid compounds serve as long-term protective intermediaries that continuously mitigate statin-induced muscle damage during prolonged therapy. This enables sustained cardiovascular protection through long-term statin use while the cannabinoid component prevents cumulative muscle toxicity and other adverse effects.
Solution Approach 2:
The cannabinoid component provides beforehand cushioning against potential statin-induced muscle damage and other adverse effects that would accumulate during long-term therapy. This protective effect is established from the outset of treatment, preventing rather than treating cumulative damage.
Data Source
AI summary
The invention relates to pharmaceutical compositions comprising a statin and a cannabinoid, and their use for the treatment of hypercholesterolemia and atherosclerosis. It has been found that compositions combining a statin and a cannabinoid are improved over existing statin formulations. The compositions of the invention for example allow for a lower effective dose of statin and a reduction of the adverse effects seen with statins taken alone. Dosing ranges and formulations suitable for oral, buccal, and sublingual administration are disclosed. Various specific cannabinoids such as cannabidiol and synthetic cannabidiols selected for their anti-inflammatory, antioxidant, and anti-atherosclerotic effect are shown to be particularly advantageous.